NIH grants over $500 million to develop antiviral drugs for potential future pandemics
- Global Surge in Mycoplasma Pneumoniae Infections Sparks Expert Warnings
- Discovery of New Targets for Treating Cancer and Age-Related Diseases
- Why Blood Sugar Levels Increase in Winter?
- Zepbound: Eli Lilly new weight-loss drug 20% cheaper than Wegovy
- US$300K: Compensation Granted as Woman Dies Following COVID-19 Vaccination
- Gut Bacteria Enhance Cancer Immunotherapy: Study Reveals Potential Role of Lactobacillus reuteri
NIH grants over $500 million to develop antiviral drugs for potential future pandemics
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
NIH grants over $500 million to develop antiviral drugs for potential future pandemics
The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has awarded approximately $577 million to establish nine Pandemic Pathogen Antiviral Drug Discovery (AViDD) centers.
The AViDD Center will conduct innovative multidisciplinary research to develop candidate COVID-19 antivirals, as well as antivirals targeting specific virus families that may cause future pandemics, including paramyxoviruses, bunyaviruses, togaviruses , filoviruses (including Ebola virus and Marburg virus), picornaviruses (including enteroviruses and other viruses that cause colds), flaviviruses (including those that cause yellow fever, dengue fever, and Zika), etc. .
The grant is part of the Pandemic Antiviral Initiative, an intensive research program aimed at accelerating the development of treatments for COVID-19.
The AViDD Center will conduct early identification and validation studies of novel viral targets, with a focus on identifying small molecules and biotherapeutics that directly block viral targets.
After drug candidates are identified and properties such as potency and breadth are evaluated, the most promising drugs move into late-stage preclinical development.
“Our hope is that research on antiviral drugs will better prepare us for the next pandemic,” said NIAID Director Dr. Anthony S. Fauci.
References:
[1] NIH announces antiviral drug development awards. Retrieved May 18, 2022, from https://www.nih.gov/news-events/news-releases/nih-announces-antiviral-drug-development-awards
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.